Dr. Haiqing Hua has rich experience in the field of drug discovery and development in both multi-national company and domestic pharma company; Primary inventor of multiple novel peptide, antibody and ADC molecules; Direct contribution to IND/NDA approval of biopharmaceuticals in US or China

Previously as Head of Biopharmaceuticals and Competitive Intelligence at Hansoh Pharma, leading preclinical discovery and development (nonclinical and CMC), and regulatory affairs of peptide, antibody and ADC programs. Previously as Principal Investigator at Eli Lilly, leading drug screening platform, GPCR agonist/antagonist and antibody discovery programs

Postdoc in stem cell and gene therapy at Columbia University Medical Center (New York), PhD in neurodegenerative diseases from University of Zurich (Switzerland), and BS from Tsinghua University in China